Oncternal Therapeutics Inc expected to post a loss of 24 cents a share - Earnings Preview

Oncternal Therapeutics

02/11/2022 02:11

* Oncternal Therapeutics Inc  ONCT.OQ   ONCT.O  is expected
to show a fall in quarterly revenue when it reports  results on
November 3. 
    * The San Diego California-based  company is expected to
report  a
85.6% decrease in revenue to $305.8 thousand from $2.13 million
a year ago, according to the mean estimate from 5 analysts,
based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for Oncternal
Therapeutics
Inc is for a loss of 24 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Oncternal
Therapeutics Inc is $7​, above​ its last closing price of $1.05.
​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Jun. 30 2022  -0.22       -0.23      -0.23     Met     -0.7
 Mar. 31 2022  -0.20       -0.20      -0.20     Met     1.2
 Dec. 31 2021  -0.24       -0.25      -0.16     Beat    35​
 Sep. 30 2021  -0.20       -0.16      -0.19     Missed  -18.7
 ​​Jun.        -0.14       -0.14      -0.16     Missed  -16.4
 30 2021                                                
 Mar. 31 2021  -0.10       -0.10      -0.12     Missed  -20​
 Dec. 31 2020  -0.19       -0.18      -0.09     Beat    50
 Sep. 30 2020  -0.30       -0.30      -0.22     Beat    26.7
 This summary was machine generated November 2 at 02:11 GMT.  All
figures in US dollars  unless otherwise stated